PO.MCB03.02 · 分子与细胞生物学

HER2 overexpression confers osimertinib resistance in EGFR-mutant lung cancer

编号 3297 展板 4 时间 4/20 02:00–05:00 区域 Section 24 主讲 Gaku Yamamoto, MD;PhD

分会场 RTK-ERBB-PI3K and New Targets in Therapeutic Resistance

查看完整资料下载 PDF 登录后可访问当前开放资料 AACR 官方页面 ↗

作者与单位

Gaku Yamamoto, Yu Tanaka, Miku Tsukuda, Sato Sayaka, Saori Matsui, Tetsuya Sakai, Hiroki Izumi, Eri Sugiyama, Yoshitaka Zenke, Shigeki Umemura, Kiyotaka Yoh, Koichi Goto, Hibiki Udagawa

National Cancer Center Hospital East, Kashiwa, Japan

摘要 Abstract

HER2 amplification has been identified in 2-5% of patients with EGFR-mutant lung cancer who have acquired resistance to osimertinib; however, its precise mechanisms in mediating resistance remain unclear. This study aims to elucidate how HER2 aberration contributes to acquired resistance to osimertinib through multiple preclinical approaches. EGFR-mutant cell lines stably overexpressing HER2 were generated by lentiviral transduction using PC9 (EGFR exon 19 deletion) and H1975 (EGFR L858R). Although HER2-overexpressing cells displayed comparable short-term (3-day) sensitivity to osimertinib in vitro relative to empty-vector controls, long-term assays (>7 days) revealed a remarkable increase in resistant colony formation across both HER2-overexpressing models. Next, xenograft models bearing HER2-overexpressing cells were established in nude mice to evaluate in vivo responses to osimertinib. Continuous oral administration of osimertinib induced initial tumor shrinkage in HER2-overexpressing xenografts; however, these tumors subsequently demonstrated pronounced regrowth, whereas parental tumors exhibited more durable responses. Finally, the combination of a HER2-targeted tyrosine kinase inhibitor and osimertinib synergistically suppressed tumor cell growth in HER2-overexpressing EGFR-mutant cells. In conclusion, HER2 overexpression induced acquired resistance to osimertinib, whereas dual HER2/EGFR blockade overcame this resistance, highlighting this approach as a promising therapeutic strategy for EGFR-mutant lung cancer.

利益披露 Disclosure

G. Yamamoto, None.. Y. Tanaka, None.. M. Tsukuda, None.. S. Sayaka, None.. S. Matsui, None. T. Sakai, Amgen ). Ono ). Chugai ). NEC ). AstraZeneca Other, honoraria for lectures. Novartis Other, honoraria for lectures. Thermo Fisher Other, honoraria for lectures. Takeda Other, honoraria for lectures. Olympus Other, honoraria for lectures. Taiho Other, honoraria for lectures. Chugai Other, honoraria for lectures. MSD Other, honoraria for lectures. Merck Other, honoraria for lectures. Daiichi Sankyo Other, honoraria for lectures. Riken Genesis Other, honoraria for lectures. Amco Other, honoraria for lectures. H. Izumi, Amgen ). Eisai ). Takeda ). BMS Japan ). Chugai ). AstraZeneca ). Ono ). MSD ). Merck ). E. Sugiyama, None. Y. Zenke, AstraZeneca ). Daiichi Sankyo ). Amgen ). GSK ). Roche ). MSD ). Merck ). AstraZeneca Other, honoraria for lectures. Lilly Other, honoraria for lectures. Chugai Other, honoraria for lectures. Ono Other, honoraria for lectures. BMS Other, honoraria for lectures. Takeda Other, honoraria for lectures. Boehringer Other, honoraria for lectures. Taiho Other, honoraria for lectures. MSD Other, honoraria for lectures. Novartis Other, honoraria for lectures. Pfizer Other, honoraria for lectures. Nihon Kayaku Other, honoraria for lectures. Kyowa Kirin Other, honoraria for lectures. S. Umemura, Taiho ). Lilly ). MSD ). MSD Other, honoraria for lectures. Chugai Other, honoraria for lectures. Takeda Other, honoraria for lectures. AstraZeneca Other, honoraria for lectures. Daiichi Sankyo Other, honoraria for lectures. K. Yoh, Abbvie ). Amgen ). ArriVent ). AstraZeneca ). Boehringer ). Chugai ). Daiichi Sankyo ). Lilly ). MSD ). Taiho ). Takeda ). Boehringer Ingelheim Other, consulting fees. Abbvie Other, consulting fees. Amgen Other, honoraria for lectures. AstraZeneca Other, honoraria for lectures. BMS Other, honoraria for lectures. Chugai Other, honoraria for lectures. Daiichi Sankyo Other, honoraria for lectures. Kyowa Kirin Other, honoraria for lectures. Lilly Other, honoraria for lectures. K. Goto, Amgen ). Astellas ). AstraZeneca ). Boehringer ). BMS ). Chugai ). Daiichi Sankyo ). Eisai ). Janssen ). Kyowa Kirin ). Merck ). MBL ). MSD ). Novartis ). ONO ). Pfizer ). Sumitomo ). Taiho ). Lilly ). Bayer ). H. Udagawa, Takeda ). Boehringer Ingelheim ). Amgen ). Taiho ). MSD ). Daiichi Sankyo Other, honoraria for lectures. Chugai Other, honoraria for lectures. Novartis Other, honoraria for lectures. Taiho Other, honoraria for lectures. MSD Other, honoraria for lectures.

在会议检索中打开